VYNE Therapeutics Inc. (VYNE) Stock Profile — Insider Trades & Financials

EPS$-0.62

Market Cap$20.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

David Domzalski

CEO & Executive Director

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The companyâs lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Founded: 2003
Employees: 10

⚡

Core Efficiency

D/E Ratio?

0.09

📊

Profitability Ratios

Current Ratio?

12.53

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 11, 2026 (in 93 days)

Annual Report (10-K) — Based on filing pattern

Jul 11, 2026

Predicted10-K

Feb 27, 2026

10-KQ4 202515d after period end

Aug 14, 2025

10-QQ2 20257d after period end

May 8, 2025

10-QQ1 20257d after period end

Mar 6, 2025

10-KQ4 20247d after period end

Nov 7, 2024

10-QQ3 20246d after period end

Aug 14, 2024

10-QQ2 20247d after period end

May 9, 2024

10-QQ1 20247d after period end

Mar 1, 2024

10-KQ4 20238d after period end

Loading company sections...

VYNE Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness